CASE 4-30361B/C1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF
BERNHARD PETER NEUMANN
APPLICATION NO: To be assigned
FILED: To be assigned
FOR: BENZOTHIADIAZOLES AND DERIVATIVES

Assistant Commissioner for Patents
Washington, D.C. 20231

PRELIMINARY AMENDMENT

Sir:

Prior to the examination of the above-referenced patent application, please amend the subject application as follows:

IN THE SPECIFICATION

Page 1, directly beneath the title, please insert:

--This application is a continuation of U.S. Application 09/601,463, filed August 2, 2000, which is a 371 of International Application PCT/EP99/00622, filed February 1, 1999.--

IN THE CLAIMS

Please amend claims 4-9 as follows:

4. (Amended) A compound of claim 1 in free base or pharmaceutically acceptable acid addition salt form, for use as a pharmaceutical.

5. (Amended) A compound of claim 1 in free base or pharmaceutically acceptable acid salt form, for use in the treatment of any state with increased endogenous level of CRF or in which the HPA is disregulated, or of a disease induced or facilitated by CRF.

6. (Amended) A pharmaceutical composition comprising a compound of claim 1 in free base or pharmaceutically acceptable acid addition salt form, in association with a pharmaceutical carrier or diluent.

7. (Amended) The use of a compound of claim 1 in free base or pharmaceutically acceptable acid addition salt form, as a pharmaceutical for the treatment of any state with increased endogenous level of CRF or in which the HPA is disregulated, or of a disease induced or facilitated by CRF.

8. (Amended) The use of a compound of claim 1 in free base or pharmaceutically acceptable acid addition salt form, for the manufacture of a medicament for the treatment of any state with increased endogenous level of CRF or in which the HPA is disregulated, or of a disease induced or facilitated by CRF.

9. (Amended) A method for the treatment of any state with increased endogenous level of CRF or which the HPA is disregulated, or of a disease induced or facilitated by CRF in a subject in need of such treatment, which comprises administering to such subject a therapeutically effective amount of a compound of claim 1 in free base or pharmaceutically acceptable acid addition salt form.

REMARKS

By the foregoing amendment to the specification, a cross-reference has been inserted beneath the title of page 1.

Claims 4-9 have been amended to eliminate multiple dependencies and correct editorial errors.

Favorable consideration of this application is respectfully requested.

Attached hereto is a marked-up version of the changes made to the claims by the current amendment. The attached page is captioned "VERSION WITH MARKINGS TO SHOW CHANGES MADE."

Respectfully submitted,

Novartis Pharmaceuticals Corporation
Patent and Trademark Dept.
564 Morris Avenue
Summit, NJ 07901-1027
(908) 522-6921

Joseph J. Borovian
Agent for Applicant
Reg. No. 26,631

Date: February 15, 2002

VERSION WITH MARKINGS TO SHOW CHANGES MADE

4. A compound of claim 1 ~~or 2~~ in free base or pharmaceutically acceptable acid addition salt form, for use as a pharmaceutical.

5. A compound of claim 1 ~~or 2~~ in free base or pharmaceutically acceptable acid salt form, for use in the treatment of any state with increased endogenous level of CRF or in which the HPA is disregulated, or of a disease induced or ~~faciliated~~ facilitated by CRF.

6. A pharmaceutical composition comprising a compound of claim 1 ~~or 2~~ in free base or pharmaceutically acceptable acid addition salt form, in association with a pharmaceutical carrier or diluent.

7. The use of a compound of claim 1 ~~or 2~~ in free base or pharmaceutically acceptable acid addition salt form, as a pharmaceutical for the treatment of any state with increased endogenous level of CRF or in which the HPA is disregulated, or of a disease induced or ~~faciliated~~ facilitated by CRF.

8. The use of a compound of claim 1 ~~or 2~~ in free base or pharmaceutically acceptable acid addition salt form, for the manufacture of a medicament for the treatment of any state with increased endogenous level of CRF or in which the HPA is disregulated, or of a disease induced or ~~faciliated~~ facilitated by CRF.

9. A method for the treatment of any state with increased endogenous level of CRF or in which the HPA is disregulated, or of a disease induced or ~~faciliated~~ facilitated by CRF in a subject in need of such treatment, which comprises administering to such subject a therapeutically effective amount of a compound of claim 1 ~~or 2~~ in free base or pharmaceutically acceptable acid addition salt form.